Relationship between mitochondrial DNA alteration and gastric cancer

doi:10.3760/cma.j.issn.1673-422X.2016.08.017

Abstract

Abstract: Mitochondrial DNA (mtDNA) is more susceptible to oxidative damage and has a higher mutation rate compared with nuclear DNA due to the absence of protective histone proteins and imperfect repair system. Somatic alterations in mtDNA have been proposed to contribute to initiation and progression of human cancer in previous researches. However, the role of these mtDNA alterations in gastric cancer progression remains unclear. Point mutations and mtDNA content alterations are the two most common mtDNA alterations that result in mitochondrial dysfunction in gastric cancers. Identifing somatic mtDNA alterations in gastric cancers as well as their association with the clinicopathological parameters of gastric cancer, and exploring the causative factors of the somatic mtDNA alterations in cancer progression have been a new direction of gastric cancer research in recent years.

Key words: DNA, mitochondrial, Mutation, Stomach neoplasms

Lin Li, Zhou Fuxiang. Relationship between mitochondrial DNA alteration and gastric cancer[J]. Journal of International Oncology, 2016, 43(8): 628-630.

References

［1］ Ahn HS, Yook JH, Park CH, et al. General perioperative management of gastric cancer patients at high-volume centers［J］. Gastric Cancer， 2011， 14(2): 178-182. DOI: 10.1007/s10120-011-0012-x. ［2］ Wei L, Zhao Y, Guo TK, et al. Association of mtDNA Dloop polymorphisms with risk of gastric cancer in Chinese population［J］. Pathol Oncol Res, 2011, 17(3): 735-742. DOI: 10.1007/s12253-011-9378-7. ［3］ Grzybowska-Szatkowska L, Slaska B. Mitochondrial DNA and carcinogenesis (review) ［J］. Mol Med Rep, 2012, 6(5): 923-930. DOI: 10.3892/mmr.2012.1027. ［4］ Hung WY, Wu CW, Yin PH, et al. Somatic mutations in mitochondrial genome and their potential roles in the progression of human gastric cancer［J］. Biochim Biophys Acta, 2010, 1800(3): 264-270. DOI: 10.1016/j.bbagen.2009.06.006. ［5］ Zhang G, Qu Y, Dang S, et al. Variable copy number of mitochondrial DNA (mtDNA) predicts worse prognosis in advanced gastric cancer patients［J］. Diagn Pathol, 2013, 8: 173. DOI: 10.1186/1746-1596-8-173. ［6］ Wang C, Wang Y, Wang H, et al. Mitochondrial DNA haplogroup N is associated good outcome of gastric cancer［J］. Tumour Biol, 2014, 35(12): 12555-12559.DOI: 10.1007/s13277-014-2575-8. ［7］ Raffoul JJ, Heydari AR， Hillman GG. DNA repair and cancer therapy: targeting APE1/Ref-1 using dietary agents［J］. J Oncol， 2012, 2012， 370481. DOI: 10.1155120121370481. ［8］ Lee HC, Chang CM, Chi CW. Somatic mutations of mitochondrial DNA in aging and cancer progression［J］. Ageing Res Rev, 2010, 9(Suppl 1): S47-S58. DOI: 10.1016/j.arr.2010.08.009. ［9］ Wallace DC. Mitochondria and cancer［J］. Nat Rev Cancer, 2012, 12(10): 685698.DOI: 10.1038/nrc3365. ［10］ Wallace DC. A mitochondrial bioenergetic etiology of disease［J］. J Clin Invest, 2013, 123(4): 1405-1412. DOI: 10.1172/JCI61398. ［11］ Schon EA, DiMauro S, Hirano M. Human mitochondrial DNA: roles of inherited and somatic mutations［J］. Nat Rev Genet, 2012, 13(12): 878-890. DOI: 10.1038/nrg3275. ［12］ Hung WY, Lin JC, Lee LM, et al. Tandem duplication/triplication correlated with poly-cytosine stretch variation in human mitochondrial DNA Dloop region［J］. Mutagenesis, 2008, 23(2): 137-142. DOI: 10.1093/mutage/gen002. ［13］ Lee HC, Wei YH. Mitochondrial DNA instability and metabolic shift in human cancers［J］. Int J Mol Sci, 2009, 10(2): 674-701. DOI: 10.3390/ijms10020674 ［14］张伟, 韩东升, 任淑红, 等. 胃癌线粒体D-loop(CA)n和ND1及ND5基因突变的研究［J］. 中华肿瘤防治杂志， 2013， 20（17）: 1327-1330, 1335. ［15］ Lee HC, Huang KH, Yeh TS, et al. Somatic alterations in mitochondrial DNA and mitochondrial dysfunction in gastric cancer progression［J］. World J Gastroenterol, 2014, 20(14): 3950-3959. DOI: 10.3748/wjg.v20.i14.3950. ［16］ Wen SL, Zhang F, Feng S. Decreased copy number of mitochondrial DNA: a potential diagnostic criterion for gastric cancer［J］. Oncol Lett, 2013, 6(4): 1098-1102. ［17］ Cook CC, Higuchi M. The awakening of an advanced malignant cancer: an insult to the mitochondrial genome［J］. Biochim Biophys Acta, 2012, 1820(5): 652-662. DOI: 10.1016/j.bbagen.2011.08.017. ［18］ Dai JG, Zhang ZY, Liu QX, et al. Mitochondrial genome microsatellite instability and copy number alteration in lung carcinomas［J］. Asian Pac J Cancer Prev, 2013, 14(4): 2393-2399. ［19］ Lee H, Lee JH, Kim DC, et al. Is mitochondrial DNA copy number associated with clinical characteristics and prognosis in gastric cancer? ［J］. Asian Pac J Cancer Prev, 2015, 16(1): 87-90. ［20］ Yu M. Generation, function and diagnostic value of mitochondrial DNA copy number alterations in human cancers［J］. Life Sci, 2011, 89(34): 65-71. DOI: 10.1016/j.lfs.2011.05.010. ［21］ Liao LM, Baccarelli A, Shu XO, et al. Mitochondrial DNA copy number and risk of gastric cancer: a report from the Shanghai Women′s Health Study［J］. Cancer Epidemiol Biomarkers Prev, 2011, 20(9): 1944-1949. DOI: 10.1158/1055-9965.EPI-11-0379. ［22］ Li H, Liu D, Lu J, et al. Physiology and pathophysiology of mitochondrial DNA［J］. Adv Exp Med Biol, 2012, 942(1): 39-51. DOI: 10.1007/978-94-007-2869-1_2.

[1]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[2]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[3]	Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165.
[4]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[5]	Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer [J]. Journal of International Oncology, 2023, 50(8): 489-492.
[6]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu. Level of serum FABP1 and its relationship with Helicobacter pylori infection in patients with gastric cancer [J]. Journal of International Oncology, 2023, 50(6): 336-341.
[7]	Li Bin, Zhang Guifang, Zhou Linjing, Yang Xiaodong, He Qiuli, Jia Sisi, Huang Puchao, Liang Jiaxin. Relationships between PIK3CA gene status and clinical features and prognosis in triple-negative breast cancer [J]. Journal of International Oncology, 2023, 50(5): 263-267.
[8]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[9]	Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen. Correlation between blood lipid level and gastric cancer [J]. Journal of International Oncology, 2023, 50(3): 183-185.
[10]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen. Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 112-116.
[11]	Yang Jun, Li Rong, Zeng Jianchang. Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 82-86.
[12]	Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757.
[13]	Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan. Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer [J]. Journal of International Oncology, 2023, 50(11): 677-682.
[14]	Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei. Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(10): 631-635.
[15]	Zhang Jingxian, Su Jianfei, Wei Xueqin, Yi Dan, Li Xiaojiang. Treatment status of non-small cell lung cancer with METexon14 skipping mutation [J]. Journal of International Oncology, 2023, 50(1): 37-41.